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RESEARCH ARTICLE Open Access
Quality of life effects of androgen
deprivation therapy in a prostate cancer
cohort in New Zealand: can we minimize
effects using a stratification based on the
aldo-keto reductase family 1, member C3
rs12529 gene polymorphism?
Nishi Karunasinghe1* , Yifei Zhu1, Dug Yeo Han2, Katja Lange1, Shuotun Zhu1, Alice Wang1, Stephanie Ellett1,
Jonathan Masters3, Megan Goudie3, Justin Keogh4,5,6, Benji Benjamin7, Michael Holmes8
and Lynnette R. Ferguson1,2
Abstract
Background: Androgen deprivation therapy (ADT) is an effective palliation treatment in men with advanced
prostate cancer (PC). However, ADT has well documented side effects that could alter the patient’s health-related
quality of life (HRQoL). The current study aims to test whether a genetic stratification could provide better
knowledge for optimising ADT options to minimize HRQoL effects.
Methods: A cohort of 206 PC survivors (75 treated with and 131 without ADT) was recruited with written consent
to collect patient characteristics, clinical data and HRQoL data related to PC management. The primary outcomes
were the percentage scores under each HRQoL subscale assessed using the European Organisation for Research
and Treatment of Cancer Quality of Life questionnaires (QLQ-C30 and PR25) and the Depression Anxiety Stress
Scales developed by the University of Melbourne, Australia. Genotyping of these men was carried out for the
aldo-keto reductase family 1, member C3 (AKR1C3) rs12529 single nucleotide polymorphism (SNP). Analysis of
HRQoL scores were carried out against ADT duration and in association with the AKR1C3 rs12529 SNP using the
generalised linear model. P-values <0 · 05 were considered significant, and were further tested for restriction with
Bonferroni correction.
Results: Increase in hormone treatment-related effects were recorded with long-term ADT compared to no ADT.
The C and G allele frequencies of the AKR1C3rs12529 SNP were 53·4 % and 46·6 % respectively. Hormone treatment-
related symptoms showed an increase with ADT when associated with the AKR1C3 rs12529 G allele. Meanwhile,
decreasing trends on cancer-specific symptoms and increased sexual interest were recorded with no ADT when
associated with the AKR1C3 rs12529 G allele and reverse trends with the C allele. As higher incidence of cancer-
specific symptoms relate to cancer retention it is possible that associated with the C allele there could be higher
incidence of unresolved cancers under no ADT options.
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Conclusions: If these findings can be reproduced in larger homogeneous cohorts, a genetic stratification
based on the AKR1C3 rs12529 SNP, can minimize ADT-related HRQoL effects in PC patients. Our data
additionally show that with this stratification it could also be possible to identify men needing ADT for better
oncological advantage.
Keywords: Health related quality of life (HRQoL), Androgen deprivation therapy (ADT), AKR1C3 rs12529 single
nucleotide polymorphism (SNP)
Background
Androgen deprivation therapy (ADT) is an effective
treatment in men with advanced metastatic PC and
those with high risk tumors in combination with
radiation therapy (RT) [1]. The main types of medical
castration methods used in New Zealand are the
luteinizing hormone-releasing hormone (LHRH) ago-
nists and the anti-androgens (AA). The LHRH agonists
suppress the gonadotropin-releasing hormone receptors
at the hypothalamus. This subsequently affects the pro-
duction of luteinizing hormone and follicular stimulating
hormone at the pituitary resulting in reduced testicular
androgen production for up to 97 % [2]. However, Labrie
[2] suggests that 41 % of the total androgen pool still
remains in the serum after LHRH agonist treatment due
to the existence of other androgen sources. Androgen is
also produced in the prostate by adrenal derived dehy-
droepiandrosterone [3]. The type 5 17-hydroxysteroid
dehydrogenase [aldo-keto reductase family 1, member
C3 (AKR1C3)], which is produced in many tissue types
including the adrenal gland also converts androstene-
dione to androgen [4]. The AAs such as Flutamide and
Bicalutamide mainly target the hormone-binding pocket
of the androgen receptor (AR) ligand-binding domain
[5]. However, in patients with high tumour burden and
with metastatic disease, AA monotherapy does not pro-
vide castration as with LHRH agonists [6].
Both surgical and medical strategies of ADT have well
documented side effects altering patient’s HRQoL [7].
Some of these symptoms are common between LHRH
agonists and AAs while some others have more pro-
nounced side effect than others [7, 8].
We have previously assessed androgen pathway related
gene polymorphisms for their association with the serum
PSA level, which is a downstream product of androgen
binding to androgen receptor (AR) [9]. This has shown
that compared with controls among PC patients an
increase in the AKR1C3 rs12529 G allele is associated
with a suppression of the serum PSA level when influ-
enced by confounders including smoking [10]. There-
fore, it could be possible that men carrying the AKR1C3
rs12529 G allele also carry lower androgen levels; when
interacting with confounders. The AKR1C3 gene located
at chromosomal position 10p15 [11], records a non-
synonymous SNP rs11551177 [11] associated with serum
testosterone levels [12]. The non-synonymous SNP
rs12529 located in exon 1 of the AKR1C3 gene [13] is in
linkage disequilibrium with the promoter SNP
rs1937845. Additionally, rs12529 SNP is located closer
to transcription factor binding sites for the antioxidant
responsive element and an activator protein-1 [14]. The
flanking region of −104 to + 65 of this gene contains a
reverse CCAAT and a GC box which are known for
transcription regulation; mutation of the GC box is
affected by SP3 transcription factor regulated reduction
of AKR1C3 activity by 70 % [15]. Meanwhile, the
polymorphism rs3763676 located at −138 is reported to
produce a 2.2 fold increase of promoter activity by
dihydrotestosterone [15]. Together these facts provide a
possibility for the AKR1C3 gene to produce differential
expression levels and thus alter subsequent contribution
to total androgen production. The AKR1C3 rs12529 has
not appeared under genome-wide association studies
(GWAS) related to PC, possibly due to its pro-cancer
modulation effects getting pronounced only after
interaction with confounders [10, 16]. An alternate
approach to GWAS has shown that the AKR1C3
rs4881400 SNP is associated with risk of sporadic PC
among Caucasians [17].
The current analysis is an attempt to assess whether
the HRQoL impacts with ADT are associated with the
AKR1C3 rs12529 SNP.
Methods
Patient recruitment
Men with confirmed clinical diagnoses of PC and
registered with the Urology Department databases at
hospitals managed under the District Health Boards of
Auckland, Waitemata, and Counties Manukau, and
patients attending private Urology and Oncology clinics
from Auckland and Hamilton, in New Zealand (NZ)
were invited to take part in this study. They were invited
directly at recruitment to urology studies or subsequent
to being in our database since 2006. A total of 206
interested patients were enrolled in this study with their
written consent. A flowchart indicating the procedure
for collection of survey data is presented in Fig. 1.
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Patient characteristics
At recruitment, self-reported ethnicity, age at PC diagno-
sis, body mass index (BMI), tobacco smoking and alcohol
consumption status, Gleason score, cancer staging data
(if available) and PC treatment type/s were recorded
at a clinical setting. Classification into Caucasian-
associated or Maori, Pacific and East Asian-associated
groups was based on our previous studies [18].
Summary of questionnaire administered
The survey questionnaire consisted of parts A, B1 and B2
Part A recorded PC management options received and
details on treatment duration. Management options
included active surveillance (AS), watchful waiting (WW),
radical prostatectomy (RP), RT including brachytherapy
(BT) and ADT. The ADT options provided in the
questionnaire were LHRH agonists, surgical orchiectomy,
AA and estrogen therapy. The final analyses considered
LHRH agonists, AA and estrogen treatments under ADT
and were further stratified as short-term (less than six
months) or long-term (over six months) treatments. If a
patient had any ADT combined with other treatments
(RT/BT), they were placed under ADT. All other PC
management methods were considered under no ADT
category. Patient reported treatment types were verified
against available clinical records.
Part B recorded HRQoL effects post-treatment or
post-diagnosis for those who were on AS or WW. Ques-
tionnaires were modified with a variation to fit in the
requirements of this study by changing the period of the
HRQoL data recording from that of the ‘past week’ as
mentioned in the original to ‘period of worst HRQoL
effects post-diagnosis’. Part B1 contained Quality of Life
Core Questionnaire, EORTC -QLQ-C30, (Version 3 · 0)
[19] and EORTC QLQ PR-25 (phase IV) [20] with
permission from the EORTC. The total score for each
domain was transformed to a percentage scale using
respective guidelines [20, 21]. All questions in Part B.2
were adapted and scored based on the Common Assess-
ment Measures: Depression Anxiety Stress Scales (DASS),
Fig. 1 Flowchart to show patient recruitment and data collection process for the Quality of Life Survey. The HRQoL data collection was carried
out with new recruits from March 2013- November 2014. In May 2013 a list of National Health Index numbers of all patients in our Urology
study database was sent to the Analytical Services of the MOH, New Zealand, to check for any recorded mortalities among patients recruited.
This check was carried out subsequent to approval from the HDEC, the MOH, New Zealand (ethics reference NTY/05/06/037/AM02). In November
2013, upon receiving this information from the Analytical Services of the MOH, all PC survivors in our patient cohort who have not yet completed
the PC treatment/HRQoL survey, were invited to take part. Therefore, the final number of patients that took part in this survey was dependent on
patient response to these invitations. (*Number assumed to have received the invitation includes PC survivors who completed the survey, those
that declined and those assumed to have received the invitation.)
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the Australian Centre for Posttraumatic Mental Health,
University of Melbourne [22]. Scoring was carried out
only where >60 % of questions under each HRQoL
subscale tested were answered.
Genotype analysis
At patient recruitment, non-fasting blood samples were
collected into coded 6.00ml EDTA BD Vacutainer® blood
collection tubes and placed on ice before being trans-
ported to our laboratory. A total of 195 patients have
supplied a blood sample at recruitment. DNA was
extracted using the QIAamp genomic DNA kit (from
Qiagen, Hilden, Germany) using the QIAcube (from
Qiagen, Hilden, Germany). Initial SNP genotyping was
carried out using the Sequenom MassArray system ac-
cording to manufacturer’s instructions (Sequenom, San
Diego, CA, USA) as described in Ferguson et al. [23].
The TaqMan® SNP Genotyping Assay using allele-
specific, dual-labelled hybridization probes from a-
predesigned assay on demand (C__8723970_1_) from the
Applied Biosystems was used for subsequent genotyping
as described before [23]. Additional details on SNP geno-
typing procedure are given in Additional file 1: Table S1.
Statistical analysis
As HRQoL effects can change with age, BMI, tobacco
smoking and clinical Gleason score, statistical variability
of these parameters between ADT and no ADT groups
was assessed and considered for HRQoL data correction.
Prostate cancer management types including RP, RT,
ADT and AS have all been reported as having a bias to-
wards HRQoL effects compared to men without PC
[24]. Therefore, treatment types were not considered for
correction in this analysis.
Categorical variables were described as frequency and
percentage between those that received ADT and those
that did not. These variables were compared between
the two groups using the Fisher’s exact test. Continuous
variables were described as mean and standard deviation
or median and 75th percentile. Medians were compared
using the Mann–Whitney U statistics. The generalised
linear model was used to test variables between those
that received ADT and those that did not. The ADT
group was standardised against the no ADT group.
The generalised linear model was also used to test the
association between the HRQoL scores and ADT treat-
ment duration as well as for testing the AKR1C3
rs12529 G allele association with and without ADT
treatment. For testing association of the HRQoL scores
between ADT duration, short- and long-term treatment
scores were standardised against no ADT group. The
relative differences between the no ADT and ADT
groups were given as estimates with 95 % CI. Changes in
the HRQoL scores as the G allele number increased
(from 0 to 1 to 2) were given as estimates with 95 % CI
for both ADT and no ADT groups. The HRQoL results
were presented as before and after adjustments for
significant confounding variables between the ADT and
no ADT groups and will be hereafter referred to as
before and after corrections. There was not enough
response data to analyse dyspnoea and appetite loss
when the data were stratified between, short- and long-
term ADT and no ADT and were excluded from analysis
between the HRQoL scores and ADT duration. For the
analysis of gene association related to the HRQoL scores
with combined types of ADT, all the HRQoL subscales
were included.
Statistical significance for variation of patient character-
istics was set at p < 0 · 05. To avoid false positives with
multiple testing, statistical significance was restricted by
Bonferroni correction under each HRQoL subscale. Ana-
lyses were carried out using SAS (v9 · 4 SAS Institute,
Cary, NC, USA) or the R statistical software [25].
Results
Demographic, lifestyle and clinical characteristics
Patient characteristics between ADT and no ADT groups
are given in Table 1. Age at diagnosis (69 · 9 ± 7 · 9y vs
65 · 3 ± 7 · 7y), p < 0 · 0001) and alcohol consumption (48
% vs 67 %, p = 0 · 0068) were significantly different
between the groups. A higher proportion (56 · 7 %) of
patients with Gleason score ≥7(4 + 3) have received
ADT, while only 43.2 % of patients with Gleason score
≤7(3 + 4) have received this treatment (p = 0 · 0005).
There was a significant difference between ADT and
no ADT groups with regards to staging data be-
tween ≤ T3a, >T3a and the group with no available
staging data (p = 0·0005).
Table 2 presents a stratification of patient-declared
treatment types at the time of the survey. Those who
reported taking ADT have selected the options of either
LHRH agonists or AA as monotherapies or in combin-
ation. The ADTs have been received on their own or in
association with RT. Among this cohort, 63 · 6 % have
had no ADT while 25 · 7 % had it long-term, and 10 · 7 %
short-term. Among ADT recipients, 85 · 3 % have used
AA. The majority of those who have not received
ADT have undergone RP (35 · 4 % without further
treatment and 9 · 2 % with RT). RT or BT on their own
was used by 7 · 3 % while 11 · 7 % have indicated being
on AS or WW.
Genotyping
Genotype data is given for 191 (Additional file 2:Table
S2) participants (CC = 55, CG = 94, GG = 42) with C and
G allele frequencies being 53·4 % and 46·6 %
respectively.
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Quality of life assessment
Survey compliance
The valid response rates of questionnaire completion
were, 88.9 % on direct administration at recruitment and
38 · 8 % and 34 · 2 % respectively by postal and electronic
mail (Figure 1). The HRQoL survey compliance rates are
given in Table 3.
HRQoL outcomes
The mean percentage HRQoL scores estimated for this
cohort are given in Table 4. The HRQoL data evaluations
for short-and long-term ADT groups compared to those
without ADT are given in Table 5. The cognitive
function effects were significantly attenuated [−27.76
(95 % CI −42.84 to −12.67), p = 0 · 0017) while depression
was significantly increased [7 · 56 (95 % CI 4 · 51-10 · 60),
p = 0 · 0002] with long-term ADT compared to no ADT
before corrections. Long-term ADT showed significant
increases of hormone treatment-related effects compared
to no ADT both before [24 · 81 (95 % CI 14 · 64-34 · 98),
p = 0 · 0002] and after [36 · 12 (95 % CI 18 · 59-53 · 65),
p = 0 · 0046] corrections.
HRQoL outcomes in association with the AKR1C3 rs12529
SNP
The association of the AKR1C3 rs12529 G allele with
HRQoL data between ADT and no ADT groups is given
in Table 6. Hormone treatment-related symptoms
showed a significant increase with ADT when associated
with the AKR1C3 rs12529 G allele, both before [5 · 40
(95 % CI 1 · 56-9 · 24), p = 0 · 0061] and after [4 · 86 (95 %
CI 1 · 08-8 · 64), p = 0 · 0120] corrections.
Discussion
ADT related HRQoL effects in PC patients are well
known [26]. Management strategies of such issues includ-
ing psychosocial and lifestyle interventions, consideration
of comorbidities before ADT and intermittent ADT
Table 1 Patient characteristics between those undergoing ADT and no ADT
ADT Group No ADT Group
Number (%) Number (%)
Ethnic group Caucasian associated 68 (90 · 7) 124 (94 · 7) p = 0 · 3883
Māori, Pacific &East Asian 7 (9 · 3) 7 (5 · 3)
Alcohol intake No 39 (52 · 0) 43 (32 · 8) p =0·0079
Yes 36 (48 · 0) 88 (67 · 2)
Smoking status Never 31 (41 · 3) 65 (49 · 6) p = 0·5067
Past 41 (54 · 7) 62 (47 · 3)
Current 3 (4 · 0) 4 (3 · 0)
Comorbidities CVD 39 (52·0) 36 (48·0) p = 1·000
No CVD 68 (48·0) 63 (48·0)
Total comorbidities 50 (66·7) 79 (60·3) P = (0·3744)
No comorbidities 25 (33·3) 52 (39·7)
Clinical data
Gleason score ≤7 (3 + 4) 32 (43 · 2) 96 (73 · 3) p = <0 · 0001
≥7 (4 + 3) 42 (56 · 7) 35 (26 · 7)
Staging data ≤T3a 44 (58·7) 64 (48·8) P = <0·0005
>T3a 12 (16·0) 5 (3·8)
No Data available 19 (25·3) 62 (47·3)
ADT Number Mean (SD) Estimate (95 % CI) p
BMI Yes 74 27 · 45 (4 · 19) 0 · 161 (−0 · 903 – 1 · 227) 0 · 7635
No 128 27 · 28 (3 · 31) 0 · 0
Age at Diagnosis Yes 74 69 · 87 (7 · 95) 3 · 458 (0 · 931 – 5 · 986) <0 · 0001
No 129 65 · 26 (7 · 70) 0 · 0
CVD cardiovascular disease
Total comorbidities included CVD together with diabetes, gout, acid reflux, neurological disorders, arthritis, psychological disorders, asthma and epilepsy
All characteristics that showed a significant variation between the ADT and No ADT groups were subsequently corrected in the proceeding analysis, except for
staging characteristics that had 25·3 % and 47·3 % of data not available between the ADT and No ADT groups respectively
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(iADT), have been reviewed by Rhee et al. [7]. After con-
trolling for false positives, our analysis indicates a signifi-
cant gain of cognitive functions and increased depression
with long-term ADT when interacting with confounders.
The most prominent feature after long-term ADT was the
hormone treatment-related effects which were signifi-
cantly higher both before and after corrections. This latter
feature was significantly associated with the AKR1C3
rs12529 G allele both before and after corrections for
confounders. The data suggest that with each increase in
the G allele, hormone treatment-related effects increase
by a score of 5 · 4 before and 4 · 9 after corrections for con-
founders. Therefore those with the AKR1C3 rs12529 GG
genotype will have a score increase of 10 · 8 and 9 · 8 as
compared to the CC genotype before and after corrections
respectively. Therefore, the AKR1C3 rs12529 GG geno-
type associated scores for our study are 65 % and 59 %
before and after corrections respectively of the mean
hormone treatment-related effects reported in our study
(Table 4). If the same ADT regime is used for men with
the AKR1C3 rs12529 CC, CG or GG genotypes, it could
be possible that those carrying the G allele/s receive an
over-treatment and hence increased side effects. The
current findings add possibilities for better utilisation of
existing ADT drugs. It will be advantageous to study
whether the AKR1C3 rs12529 G allele carriers could
benefit with iADT usage for oncological and HRQoL
benefits; while complementing previous findings on iADT
[27]. This genotypic association of the hormone treatment-
related effects is novel and prove our hypothesis.
Our approach of considering correction for multiple
testing however could be overly conservative due to
possible non-independence of factors assessed [28, 29]
under each HRQoL scale. For instance Engstrom has
pointed out the interdependence of many HRQoL effects
subsequent to hot flush experience [29]. Therefore, for
this study it is beneficial to discuss HRQoL effects that
were recorded under a significance level of p < 0.05
without Bonferroni restriction as well. In this regard
additional recording of long-term ADT related increase
in insomnia, depression and anxiety after correction for
confounders are worth mentioning. Additionally, the
AKR1C3 rs12529 G allele associated increased effects on
emotional functioning, and decreased effects on fatigue,
dyspnoea, appetite loss, bowel symptoms, hormone
treatment-related symptoms and sexual interest (or
Table 2 Stratification of patient numbers by treatment type
Number (%) Number (%) Number (%)
ADT 75 (36 · 4) Long Term 53 (25 · 7)
LHRH + AA 5 (2 · 4)
LHRH + AA + RT 7 (3 · 4)
LHRH 3 (1 · 5)
LHRH + RT 3 (1 · 5)
AA 17 (8 · 3)
AA + RT 18 (8 · 7)
Short Term 22 (10 · 7)
LHRH + AA 1 (0 · 5)
LHRH + AA + RT 2 (1 · 0)
LHRH 3 (1 · 5)
LHRH + RT 2 (1 · 0)
AA 3 (1 · 5)
AA + RT 11 (5 · 3)
No ADT 131 (63 · 6)
AS/WW/TURP 24 (11 · 7)
RP 73 (35 · 4)
RT + BT 15 (7 · 3)
RP+ RT 19 (9 · 2)
ADT Androgen Deprivation Therapy, AA Anti androgens (eg: Cyproterone acetate, Bicalutamide, Flutamide), LHRH Luteinizing hormone- releasing hormone
agonists ((eg:Zoladex, Lucrin), AS Active Surveillance, WW Watchful Waiting, RP Radical Prostatectomy (both Laparoscopic and robotic radical prostatectomy and
classical radical prostatectomy), RT Radiation Therapy (RT), BT Brachytherapy
One patient had combination therapy with a LHRH agonist, AA and estrogen therapy and was grouped under LHRH + AA
TURP-Ttransurethral resection of the prostate was also given as an option and if selected on its own was considered under AS/WW. If TURP was indicated with
other treatment type, the other treatment had precedence
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reverse associated with the C allele) among those not
having ADT are important recordings. This could mean
that those opting for PC management methods that do
not involve ADT have a higher risk of retaining these
symptoms possibly due to untreated metastasis associ-
ated with the C allele. This could be due to higher
androgen levels associated with the C allele [10],
supporting metastasis that requires ADT. In addition to
findings from Yu et al., where increased prostate cancer-
specific mortality after ADT was observed among the
AKR1C3 rs12529 CC genotype could mean that patients
with this genotype require extended ADT treatments for
better oncological benefits. The AKR1C3 rs12529
polymorphism has been previously shown to be associ-
ated with emotional control of lifestyle behaviour [30].
AKR1C3 is considered as an endogenous neuroactive
steroid that has shown to mediate effects at the GABAA
receptors in the brain [31]. The trends of association of
the AKR1C3 rs12529 G allele with increased emotional
functioning effects and increased sexual interest in our
cohort with no ADT could have some relevance to the
GABAA receptor modulation.
Although ADT is supportive of survival advantage
for men diagnosed with advanced PC for some men,
long-term ADT may not necessarily promote a better
life; and this HRQoL suppression may even extend
beyond 18 months of treatment [32]. As commented
by Nguyen [33], evaluating short-term side effects vs
long-term oncological benefits is important in this
dialogue. Our study is adding another paradigm to
this dialogue through a genetic stratification for ADT.
If patients can be stratified based on the AKR1C3
rs12529 SNP, physicians might be able to organise
ADT regimes that will be more beneficial for both
oncological outcomes and HRQoL [7]. However, this
hypothesis needs testing in large prospective studies
with homogeneous patient cohorts.
Our study has the following shortcomings. The vari-
ation in HRQoL data recording from that of the ‘past
week’ to ‘worst HRQoL effects post-diagnosis could have
caused a symptoms recall bias. Besides HRQoL is a
complicated outcome to measure due to many confounding
Table 3 Quality of life survey compliance
Questionnaire part
(total number of questions)
Number of questions
answered
% completion
B1- EORTC QLQ-30 & PR25 (55)
55 13 · 1
54 35 · 4
53 5 · 8
47-52 41 · 5
<43 3 · 9
B2- Depression Anxiety & Stress
Scales (42)
42 92 · 2
41 5 · 3
40 1 · 0
<31 1 · 5
Part B1 exclusions-
The question regarding the use of an incontinence aid (Question number 38)
was removed from the analysis as only 29 · 6 % of participants have
completed this question. However, urinary symptom score assessed without
question 38 was significantly higher among incontinence aid users compared
to non-users [median 35·4 ((75th percentile 56·6 %) vs20·8 (75th percentile
33·3 %) with a p < 0·001 ]. Therefore, removal of question 38 has no significant
impact in our assessment
Question numbers 52–55 related to those who were sexually active over the 4
weeks prior to completion of the questionnaire were also removed from
analysis, as only 59 · 7 % have answered these questions. However, sexual
interest score assessed between those that recorded sexual activity was
significantly higher than those that have not recorded sexual activity [median
50 (75th percentile 66·6 %) vs 16·7 (75th percentile 33·3 %) with a p < 0·001].
Therefore, removal of questions 52–55 has no significant impact in
our assessment
Table 4 The mean percentage HRQoL scores estimated for the
study
QoL score tested Mean (SD)
Global health status 69 · 29 (22 · 75)
Functional scales
Physical functioning 85 · 01 (19 · 66)
Role functioning 73 · 46 (31 · 44)
Emotional functioning 83 · 02 (21 · 40)
Cognitive functioning 83 · 41 (19 · 97)
Social functioning 77 · 29 (27 · 31)
Cancer Symptoms
Fatigue 27 · 19 (26 · 32)
Nausea & vomiting 3 · 55 (12 · 87)
Pain 14 · 90 (23 · 43)
Dyspnoea 9 · 67 (20 · 76)
Insomnia 22 · 60 (28 · 03)
Appetite loss 7 · 59 (18 · 14)
Constipation 17 · 82 (26 · 63)
Diarrhoea 12 · 31 (23 · 60)
Financial difficulties 9 · 91 (21 · 49)
Prostate cancer specific symptoms
Urinary symptoms 28 · 28 (19 · 72)
Bowel symptoms 9 · 00 (14 · 15)
Hormone treatment-related symptoms 16 · 57 (16 · 59)
Sexual interest 36 · 88 (28 · 48)
Depression anxiety and stress symptoms
Depression 4 · 50 (7 · 49)
Anxiety 2 · 89 (4 · 58)
Stress 5 · 54 (7 · 52)
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Table 5 Health-related QoL scores by ADT duration in the study cohort
Before adjustment After adjustment
QoL score tested ADT Duration Estimate (95 % CI) p Estimate (95 % CI) p
Global health status Long Term −8 · 32 (−35 · 24 - 18 · 60) 0 · 5134 −2 · 92 (−69 · 57 - 63 · 73) 0 · 9090
Short Term 8 · 34 (−18 · 58 - 35 · 27) 0 · 5123 −1 · 71 (−68 · 84 - 65 · 41) 0 · 9469
No ADT 0 · 0 0 · 0
Functional scales
Physical functioning Long Term 17 · 77 (−6 · 49 - 42 · 02) 0 · 1364 24 · 77 (−53 · 63 - 103 · 16) 0 · 4299
Short Term 15 · 57 (−8 · 69 - 39 · 82) 0 · 1873 7 · 43 (−71 · 52 - 86 · 38) 0 · 8068
No ADT 0 · 0 0 · 0
Role functioning Long Term 20 · 36 (−15 · 89 - 56 · 6) 0 · 2446 28 · 56 (−74 · 75 - 131 · 88) 0 · 4855
Short Term 42 · 59 (6 · 34 - 78 · 83) 0 · 0250 46 · 35 (−57 · 7 - 150 · 40) 0 · 2838
No ADT 0 · 0 0 · 0
Emotional functioning Long Term −7 · 81 (−26 · 65 - 11 · 03) 0 · 3841 −10 · 65 (−63 · 78 - 42 · 48) 0 · 6074
Short Term 15 · 56 (−3 · 28 - 34 · 39) 0 · 0972 15 · 05 (−38 · 46 - 68 · 56) 0 · 4784
No ADT 0 · 0 0 · 0
Cognitive functioning Long Term −27 · 76 (−42 · 84 - -12 · 67) 0 · 0017 −36 · 5 (−78 · 55 - 5 · 56) 0 · 0736
Short Term 16 · 68 (1 · 59 - 31 · 77) 0 · 0330 13 · 39 (−28 · 97 - 55 · 74) 0 · 4298
No ADT 0 · 0 0 · 0
Social functioning Long Term −0 · 02 (−22 · 83 - 22 · 78) 0 · 9983 −17 · 9 (−75 · 89 - 40 · 10) 0 · 4399
Short Term 22 · 21 (−0 · 59 - 45 · 02) 0 · 0553 13 · 99 (−44 · 42 - 72 · 40) 0 · 5423
No ADT 0 · 0 0 · 0
Significance after Bonferroni correction for multiple testing was considered as p < 0·01
Cancer Symptoms scales
Fatigue Long Term 0 · 34 (−39 · 62 - 40 · 31) 0 · 9853 −12 · 7 (−107 · 37 - 81 · 98) 0 · 7285
Short Term −18 · 52 (−58 · 49 - 21 · 44) 0 · 3325 7 · 21 (−88 · 14 - 102 · 56) 0 · 8440
No ADT 0 · 0 0 · 0
Nausea and vomiting Long Term 5 · 57 (−0 · 15 - 11 · 28) 0 · 0554 4 · 63 (−8 · 94 - 18 · 20) 0 · 3972
Short Term 0 · 0 (−5 · 72 - 5 · 72) 1 · 0000 0 · 8 (−12 · 87 - 14 · 47) 0 · 8788
No ADT 0 · 0 0 · 0
Pain Long Term −14 · 43 (−36 · 64 - 7 · 78) 0 · 1822 6 · 04 (−51 · 14 - 63 · 22) 0 · 7839
Short Term −16 · 67 (−38 · 88 - 5 · 54) 0 · 1280 −14 · 31 (−71 · 9 - 43 · 27) 0 · 5281
No ADT 0 · 0 0 · 0
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Table 5 Health-related QoL scores by ADT duration in the study cohort (Continued)
Insomnia Long Term 18 · 50 (−5 · 23 - 42 · 23) 0 · 1152 39 · 7 (1 · 95 - 77 · 44) 0 · 0432
Short Term −3 · 70 (−27 · 43 - 20 · 03) 0 · 7400 17 · 39 (−20 · 62 - 55 · 40) 0 · 2729
No ADT 0 · 0 0 · 0
Constipation Long Term −0 · 01 (−33 · 53 - 33 · 51) 0 · 9994 −18 · 91 (−109 · 24 - 71 · 42) 0 · 5923
Short Term 5 · 54 (−33 · 77 - 44 · 84) 0 · 7622 −19 · 71 (−110 · 68 - 71 · 27) 0 · 5800
No ADT 0 · 0 0 · 0
Diarrhoea Long Term −18 · 52 (−53 · 4 - 16 · 36) 0 · 2698 8 · 58 (−25 · 92 - 43 · 09) 0 · 5277
Short Term −18 · 52 (−53 · 4 - 16 · 36) 0 · 2698 −4 · 34 (−39 · 09 - 30 · 41) 0 · 7462
No ADT 0 · 0 0 · 0
Financial difficulties Long Term −14 · 81 (−43 · 53 - 13 · 91) 0 · 2832 −13 · 26 (−99 · 81 - 73 · 29) 0 · 6925
Short Term −14 · 81 (−43 · 53 - 13 · 91) 0 · 2832 −19 · 08 (−106 · 24 - 68 · 08) 0 · 5762
No ADT 0 · 0 0 · 0
Significance after Bonferroni correction for multiple testing was considered as p < 0·007
Prostate cancer- specific symptoms scales
Urinary symptoms Long Term −1 · 49 (−27 · 72 - 24 · 74) 0 · 9036 16 · 33 (−9 · 94 - 42 · 59) 0 · 1595
Short Term −14 · 82 (−41 · 05 - 11 · 41) 0 · 2419 14 · 75 (−11 · 7 - 41 · 2) 0 · 1965
No ADT 0 · 0 0 · 0
Bowel symptoms Long Term −10 · 74 (−27 · 3 - 5 · 81) 0 · 1827 8 · 82 (−22 · 07 - 39 · 71) 0 · 4721
Short Term −5 · 18 (−21 · 73 - 11 · 38) 0 · 5085 −4 · 33 (−35 · 44 - 26 · 78) 0 · 7188
No ADT 0 · 0 0 · 0
Hormonal treatment- related symptoms Long Term 24 · 81 (14 · 64 - 34 · 98) 0 · 0002 36 · 12 (18 · 59 - 53 · 65) 0 · 0046
Short Term 3 · 71 (−6 · 46 - 13 · 88) 0 · 4420 −2 · 42 (−20 · 08 - 15 · 24) 0 · 7230
No ADT 0 · 0 0 · 0
Sexual interest Long Term −6 · 29 (−43 · 63 - 31 · 05) 0 · 7200 10 · 64 (−71 · 4 - 92 · 68) 0 · 7370
Short Term −39 · 66 (−76 · 99 - -2 · 32) 0 · 0392 −10 · 9 (−93 · 52 - 71 · 73) 0 · 7328
No ADT 0 · 0 0 · 0
Significance after Bonferroni correction for multiple testing was considered as p < 0·0125
Depression anxiety and stress symptoms scales
Depression Long Term 7 · 56 (4 · 51 - 10 · 60) 0 · 0002 7 · 34 (2 · 01 - 12 · 67) 0 · 0187
Short Term −0 · 78 (−3 · 83 - 2 · 27) 0 · 5886 −0 · 96 (−6 · 33 - 4 · 41) 0 · 6448
No ADT 0 · 0 0 · 0
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Table 5 Health-related QoL scores by ADT duration in the study cohort (Continued)
Anxiety Long Term 2 · 22 (−0 · 44 - 4 · 88) 0 · 0937 5 · 33 (0 · 24 - 10 · 43) 0 · 0437
Short Term −0 · 78 (−3 · 44 - 1 · 88) 0 · 5359 −1 · 64 (−6 · 77 - 3 · 48) 0 · 4234
No ADT 0 · 0 0 · 0
Stress Long Term 3 · 56 (−2 · 47 - 9 · 58) 0 · 2225 5 · 90 (−9 · 44 - 21 · 24) 0 · 3459
Short Term −3 · 44 (−9 · 47 - 2 · 58) 0 · 2364 −1 · 41 (−16 · 86 - 14 · 04) 0 · 8123
No ADT 0 · 0 0 · 0
Significance after Bonferroni correction for multiple testing was considered as p < 0·017
Results are provided before and after adjustment for Gleason score, alcohol consumption and age at diagnosis. There was not enough response data to analyse dyspnoea and appetite loss when the data were
stratified between ADT duration. Therefore, these two sub-scales were excluded from analysis between the QoL scores and ADT duration
P values showing significance after corrections for multiple testing is given in bold text
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Table 6 Association of the AKR1C3 rs12529 G allele with health-related QoL scores in the study cohort
Before Adjustment After adjustment
QoL score tested ADT Estimate (95 % CI) p Estimate (95 % CI) p
Global health status Yes 0 · 98 (−4 · 54 - 6 · 49) 0 · 7273 0 · 72 (−5 · 04 - 6 · 49) 0 · 8051
No 3 · 35 (−2 · 34 - 9 · 04) 0 · 2476 3 · 83 (−1 · 89 - 9 · 54) 0 · 1880
Functions scales
Physical functioning Yes 3 · 18 (−1 · 53 - 7 · 88) 0 · 1846 2 · 7 (−2 · 28 - 7 · 68) 0 · 2858
No 4 · 69 (−0 · 17 - 9 · 54) 0 · 0584 4 · 66 (−0 · 28 - 9 · 59) 0 · 0642
Role functioning Yes 4 · 75 (−2 · 69 - 12 · 19) 0 · 2097 5 · 86 (−2 · 01 - 13 · 74) 0 · 1435
No 5 · 69 (−1 · 99 - 13 · 36) 0 · 1456 6 · 2 (−1 · 59 – 14 · 0) 0 · 1183
Emotional functioning Yes −1 · 05 (−6 · 19 - 4 · 09) 0 · 6872 −2 · 17 (−7 · 51 - 3 · 16) 0 · 4225
No 5 · 66 (0 · 43 - 10 · 90) 0 · 0342 6 · 03 (0 · 80 - 11 · 27) 0 · 0241
Cognitive functioning Yes −0 · 68 (−5 · 4 - 4 · 04) 0 · 7755 −0 · 74 (−5 · 76 - 4 · 29) 0 · 7725
No 3 · 53 (−1 · 34 - 8 · 40) 0 · 1549 3 · 70 (−1 · 27 - 8 · 68) 0 · 1439
Social functioning Yes −0 · 76 (−7 · 35 - 5 · 84) 0 · 8215 −0 · 47 (−7 · 49 - 6 · 55) 0 · 8943
No 1 · 68 (−5 · 13 - 8 · 49) 0 · 6275 1 · 62 (−5 · 33 - 8 · 57) 0 · 6466
Significance after Bonferroni correction for multiple testing was considered as p < 0·01
Cancer symptoms scales
Fatigue Yes 0 · 10 (−6 · 11 - 6 · 32) 0 · 9740 −1 · 05 (−7 · 61 - 5 · 51) 0 · 7531
No −8 · 49 (−14 · 82 - -2 · 15) 0 · 0089 −8 · 66 (−15 · 09 - -2 · 23) 0 · 0086
Nausea and vomiting Yes −0 · 29 (−3 · 47 - 2 · 88) 0 · 8563 −0 · 22 (−3 · 60 - 3 · 16) 0 · 8972
No −2 · 97 (−6 · 2 - 0 · 27) 0 · 0725 −2 · 94 (−6 · 25 - 0 · 38) 0 · 0821
Pain Yes −2 · 02 (−7 · 71 - 3 · 67) 0 · 4848 −0 · 45 (−6 · 41 - 5 · 51) 0 · 8822
No −3 · 45 (−9 · 25 - 2 · 35) 0 · 2420 −3 · 37 (−9 · 23 - 2 · 48) 0 · 2566
Dyspnoea Yes 0 · 95 (−4 · 06 - 5 · 95) 0 · 7098 0 · 21 (−5 · 10 - 5 · 51) 0 · 9392
No −5 · 94 (−11 · 11 - -0 · 78) 0 · 0243 −6 · 29 (−11 · 57 - -1 · 02) 0 · 0195
Insomnia Yes −2 · 19 (−8 · 97 - 4 · 60) 0 · 5257 −2 · 01 (−9 · 17 - 5 · 16) 0 · 5807
No −6 · 72 (−13 · 64 - 0 · 2) 0 · 0567 −6 · 64 (−13 · 66 - 0 · 38) 0 · 0637
Appetite loss Yes −3 · 09 (−7 · 51 - 1 · 32) 0 · 1685 −2 · 90 (−7 · 55 - 1 · 74) 0 · 2191
No −4 · 91 (−9 · 40 - -0 · 41) 0 · 0326 −4 · 62 (−9 · 18 - -0 · 06) 0 · 0473
Constipation Yes 1 · 17 (−5 · 29 - 7 · 64) 0 · 7203 2 · 77 (−4 · 01 - 9 · 54) 0 · 4214
No −1 · 13 (−7 · 71 - 5 · 45) 0 · 7352 −1 · 07 (−7 · 71 - 5 · 58) 0 · 7521
Diarrhoea Yes 2 · 41 (−3 · 17 – 8 · 00) 0 · 3953 2 · 23 (−3 · 57 - 8 · 03) 0 · 4495
No −1 · 57 (−7 · 27 - 4 · 12) 0 · 5858 −2 · 28 (−7 · 97 - 3 · 41) 0 · 4304
Financial difficulties Yes −4 · 58 (−9 · 74 - 0 · 58) 0 · 0814 −4 · 44 (−9 · 9 - 1 · 02) 0 · 1104
No −1 · 18 (−6 · 50 - 4 · 15) 0 · 6635 −1 · 58 (−6 · 98 - 3 · 83) 0 · 5656
Significance after Bonferroni correction for multiple testing was considered as p < 0·005
Prostate cancer-specific symptoms scales
Urinary symptoms Yes 0 · 58 (−4 · 22 - 5 · 39) 0 · 8105 1 · 20 (−3 · 81 - 6 · 21) 0 · 6363
No 0 · 56 (−4 · 33 - 5 · 45) 0 · 8216 0 · 26 (−4 · 65 - 5 · 17) 0 · 9178
Bowel symptoms Yes −1 · 61 (−5 · 06 - 1 · 84) 0 · 3591 −1 · 32 (−4 · 95 - 2 · 31) 0 · 4744
No −3 · 58 (−7 · 1 - -0 · 07) 0 · 0458 −3 · 85 (−7 · 41 - -0 · 30) 0 · 0337
Hormonal treatment-related symptoms Yes 5 · 40 (1 · 56 - 9 · 24) 0 · 0061 4 · 86 (1 · 08 - 8 · 64) 0 · 0120
No −4 · 18 (−8 · 1 - -0 · 27) 0 · 0364 −4 · 64 (−8 · 35 - -0 · 94) 0 · 0143
Sexual interest Yes −1 · 63 (−8 · 49 - 5 · 23) 0 · 6395 −0 · 38 (−7 · 56 - 6 · 79) 0 · 9159
No 7 · 12 (0 · 24 - 14 · 01) 0 · 0427 7 · 35 (0 · 40 - 14 · 30) 0 · 0383
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variables. However, as the outcome of symptom scores aligns
well with such quality of life studies done with original
questionnaires [32], it shows that this exercise was not
likely to have affected at least the long-term recall of
hormonal treatment-related HRQoL effects. We have
removed the questions on use of incontinence aid
and sexual activity data from the analysis. However,
the former is represented by urinary symptom score
and the latter by sexual interest score as shown in
Table 3. The study cohort was mainly Caucasian
based and therefore, the results cannot be extended
to other ethnicities. We have not defined the ADT
usage between curative and palliative requirements.
Our protocol also did not define those using AA only
for flare protection. As 85.3 % of ADT users have
received AAs, our findings could be biased towards
these treatments. The grouping of LHRH agonist and
AA treatments as a single ADT group was unavoid-
able due to the small sample size which itself is a
shortcoming. The need for grouping all with short-
and long-term ADT as one group for genetic analysis
is also a shortcoming of this analysis. As staging data
availability was limited we were not able to correct
our results with this clinical feature although adjust-
ments were carried out based on the Gleason score
data.
Conclusion
Our aim was to test whether ADT-related HRQoL ef-
fects in PC patients have an association with the
AKR1C3 rs12529 SNP. Our results indicate that the
hormone treatment-related effects have a positive
association with the AKR1C3 rs12529 G allele. There-
fore, it is advantages to assess in larger prospective
studies with better patient homogeneity whether those
with the AKR1C3 rs12529 G allele/s perform well with
iADT; and to evaluate whether the CC genotype can
tolerate extended ADT treatment, for better oncological
advantage. If proven successful, PC patients may be
genetically stratified for optimal ADT effects for both
survival benefits, and to maintain HRQoL.
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